Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Influence of Drugs on Mild Cognitive Impairment in Parkinson’s Disease: Evidence from the PACOS Study

Author(s): Calogero Edoardo Cicero*, Roberto Monastero, Claudio Terravecchia, Giulia Donzuso, Antonina Luca, Roberta Baschi, Maria Caccamo, Giovanni Mostile, Loretta Giuliano, Mario Zappia and Alessandra Nicoletti*

Volume 20, Issue 5, 2022

Published on: 29 March, 2020

Page: [998 - 1003] Pages: 6

DOI: 10.2174/1570159X20666211223122800

Price: $65

Abstract

Background: polytherapy and the anticholinergic activity of several drugs negatively influence cognition in the elderly. However, little is known on the effect on Mild Cognitive Impairment (MCI) in Parkinson’s Disease (PD).

Methods: patients with PD belonging to the baseline PACOS cohort with full pharmacological data have been included in this study. MCI diagnosis was made according to the MDS level II criteria. Polytherapy was defined as patients assuming ≥6 drugs. The anticholinergic burden has been calculated using the Anticholinergic Drug Scale (ADS). Molecules have been classified according to the ATC classification. Association with MCI has been assessed with a multivariate logistic regression analysis with MCI as the dependent variable.

Results: pharmacological data were available for 238 patients (mean age 64.7±9.7). One hundred (42.0%) were diagnosed with MCI. No association was found in the full multivariate model (correcting for age, sex, disease duration, education, UPDRS-ME, LEDD-DAs) with either polytherapy or the ADS. Concerning drug classes, anti-hypertensive medications were positively associated with PD-MCI (OR 2.02;95%CI 1.04-3.89; p=0.035) while gastroprotective agents were negatively associated (OR 0.51; 95%CI 0.27-0.99; p=0.047).

Conclusion: the magnitude of polytherapy and anticholinergic drugs burden does not appear to modulate MCI risk in PD, probably due to cautious prescription patterns. The effect of antihypertensive and gastroprotective agents on PD-MCI risk, while needing further confirmations, could be relevant for clinical practice.

Keywords: Parkinson’s disease, mild cognitive impairment, drugs, polytherapy, polypharmacy, anticholinergic burden.

« Previous Next »
Graphical Abstract

[1]
Hirsch, L.; Jette, N.; Frolkis, A.; Steeves, T.; Pringsheim, T. The incidence of Parkinson’s disease: a systematic review and meta-analysis. Neuroepidemiology, 2016, 46(4), 292-300.
[http://dx.doi.org/10.1159/000445751] [PMID: 27105081]
[2]
Nicoletti, A.; Luca, A.; Baschi, R.; Cicero, C.E.; Mostile, G.; Davì, M.; Pilati, L.; Restivo, V.; Zappia, M.; Monastero, R. Incidence of mild cognitive impairment and dementia in Parkinson’s disease: the Parkinson’s disease cognitive impairment study. Front. Aging Neurosci., 2019, 11, 21.
[http://dx.doi.org/10.3389/fnagi.2019.00021] [PMID: 30800065]
[3]
Baiano, C.; Barone, P.; Trojano, L.; Santangelo, G. Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: A meta-analysis. Mov. Disord., 2020, 35(1), 45-54.
[http://dx.doi.org/10.1002/mds.27902] [PMID: 31743500]
[4]
Monastero, R.; Cicero, C.E.; Baschi, R.; Davì, M.; Luca, A.; Restivo, V.; Zangara, C.; Fierro, B.; Zappia, M.; Nicoletti, A. Mild cognitive impairment in Parkinson’s disease: the Parkinson’s disease cognitive study (PACOS). J. Neurol., 2018, 265(5), 1050-1058.
[http://dx.doi.org/10.1007/s00415-018-8800-4] [PMID: 29478221]
[5]
McLean, G.; Hindle, J.V.; Guthrie, B.; Mercer, S.W. Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol., 2017, 17(1), 126.
[http://dx.doi.org/10.1186/s12883-017-0904-4] [PMID: 28666413]
[6]
Maher, R.L.; Hanlon, J.; Hajjar, E.R. Clinical consequences of polypharmacy in elderly. Expert Opin. Drug Saf., 2014, 13(1), 57-65.
[http://dx.doi.org/10.1517/14740338.2013.827660] [PMID: 24073682]
[7]
Carnahan, R.M.; Lund, B.C.; Perry, P.J.; Pollock, B.G.; Culp, K.R. The anticholinergic drug scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J. Clin. Pharmacol., 2006, 46(12), 1481-1486.
[http://dx.doi.org/10.1177/0091270006292126] [PMID: 17101747]
[8]
Fox, C.; Richardson, K.; Maidment, I.D.; Savva, G.M.; Matthews, F.E.; Smithard, D.; Coulton, S.; Katona, C.; Boustani, M.A.; Brayne, C. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J. Am. Geriatr. Soc., 2011, 59(8), 1477-1483.
[http://dx.doi.org/10.1111/j.1532-5415.2011.03491.x] [PMID: 21707557]
[9]
Ishii, N.; Mochizuki, H.; Sakai, K.; Ogawa, G.; Shiomi, K.; Nakazato, M. Polypharmacy associated with cognitive decline in newly diagnosed Parkinson’s disease: a cross-sectional study. Dement. Geriatr. Cogn. Disord. Extra, 2019, 9(3), 338-343.
[http://dx.doi.org/10.1159/000502351] [PMID: 31608098]
[10]
Ehrt, U.; Broich, K.; Larsen, J.P.; Ballard, C.; Aarsland, D. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J. Neurol. Neurosurg. Psychiatry, 2010, 81(2), 160-165.
[http://dx.doi.org/10.1136/jnnp.2009.186239] [PMID: 19770163]
[11]
Sheu, J-J.; Tsai, M-T.; Erickson, S.R.; Wu, C-H. Association between anticholinergic medication use and risk of dementia among patients with Parkinson’s disease. Pharmacotherapy, 2019, 39(8), 798-808.
[http://dx.doi.org/10.1002/phar.2305] [PMID: 31251824]
[12]
Litvan, I.; Goldman, J.G.; Tröster, A.I.; Schmand, B.A.; Weintraub, D.; Petersen, R.C.; Mollenhauer, B.; Adler, C.H.; Marder, K.; Williams-Gray, C.H.; Aarsland, D.; Kulisevsky, J.; Rodriguez-Oroz, M.C.; Burn, D.J.; Barker, R.A.; Emre, M. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov. Disord., 2012, 27(3), 349-356.
[http://dx.doi.org/10.1002/mds.24893] [PMID: 22275317]
[13]
Yarnall, A.J.; Lawson, R.A.; Duncan, G.W.; Breen, D.P.; Khoo, T.K.; Brooks, D.; Barker, R.A.; Taylor, J.P.; Burn, D.J. Anticholinergic load: is there a cognitive cost in early Parkinson’s disease? J. Parkinsons Dis., 2015, 5(4), 743-747.
[http://dx.doi.org/10.3233/JPD-150664] [PMID: 26444094]
[14]
Tomlinson, C.L.; Stowe, R.; Patel, S.; Rick, C.; Gray, R.; Clarke, C.E. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov. Disord., 2010, 25(15), 2649-2653.
[http://dx.doi.org/10.1002/mds.23429] [PMID: 21069833]
[15]
Folstein, M.F.; Folstein, S.E.; McHugh, P.R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res., 1975, 12(3), 189-198.
[http://dx.doi.org/10.1016/0022-3956(75)90026-6] [PMID: 1202204]
[16]
Ziad, A.; Olekhnovitch, R.; Ruiz, F.; Berr, C.; Bégaud, B.; Goldberg, M.; Zins, M.; Mura, T. Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort. J. Neurol. Neurosurg. Psychiatry, 2018, 89(10), 1107-1115.
[http://dx.doi.org/10.1136/jnnp-2018-318190] [PMID: 30196250]
[17]
Poletti, M.; Bonuccelli, U. Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson’s disease: a review. Ther. Adv. Psychopharmacol., 2013, 3(2), 101-113.
[http://dx.doi.org/10.1177/2045125312470130] [PMID: 24167681]
[18]
Shepherd, T.A.; Edelstyn, N.M.J.; Mayes, A.R.; Ellis, S.J. Second-generation dopamine agonists and recollection impairments in Parkinson’s disease. J. Neuropsychol., 2013, 7(2), 284-305.
[http://dx.doi.org/10.1111/jnp.12025] [PMID: 23815454]
[19]
Castro, E.S.; Santos-García, D.; de Deus Fonticoba, T.; Expósito Ruíz, I.; Tuñas Gesto, C.; Arribí, M.M. Causes and factors related to dopamine agonist withdrawal in Parkinson’s disease. Brain Behav., 2016, 6(7), e00453.
[http://dx.doi.org/10.1002/brb3.453] [PMID: 27247848]
[20]
Yasar, S.; Schuchman, M.; Peters, J.; Anstey, K.J.; Carlson, M.C.; Peters, R. Relationship between antihypertensive medications and cognitive impairment: part I. Curr. Hypertens. Rep., 2016, 18(8), 67.
[http://dx.doi.org/10.1007/s11906-016-0674-1] [PMID: 27492370]
[21]
Nicoletti, A.; Luca, A.; Baschi, R.; Cicero, C.E.; Mostile, G.; Davì, M.; La Bianca, G.; Restivo, V.; Zappia, M.; Monastero, R. Vascular risk factors, white matter lesions and cognitive impairment in Parkinson’s disease: the PACOS longitudinal study. J. Neurol., 2021, 268(2), 549-558.
[http://dx.doi.org/10.1007/s00415-020-10189-8] [PMID: 32865628]
[22]
Park, Y.W.; Shin, N-Y.; Chung, S.J.; Kim, J.; Lim, S.M.; Lee, P.H.; Lee, S.K.; Ahn, K.J. Magnetic resonance imaging-visible perivascular spaces in basal ganglia predict cognitive decline in Parkinson’s disease. Mov. Disord., 2019, 34(11), 1672-1679.
[http://dx.doi.org/10.1002/mds.27798] [PMID: 31322758]
[23]
Jost, W.H. What are the considerations for anti-hypertensive treatment in patients with Parkinson’s disease? Expert Opin. Pharmacother., 2020, 21(10), 1127-1130.
[http://dx.doi.org/10.1080/14656566.2020.1744565] [PMID: 32196396]
[24]
Udow, S.J.; Robertson, A.D.; MacIntosh, B.J.; Espay, A.J.; Rowe, J.B.; Lang, A.E.; Masellis, M. ‘Under pressure’: is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies? J. Neurol. Neurosurg. Psychiatry, 2016, 87(12), 1311-1321.
[http://dx.doi.org/10.1136/jnnp-2016-314123] [PMID: 27613160]
[25]
Kim, Y.J.; Tae, B.S.; Bae, J.H. Cognitive function and urologic medications for lower urinary tract symptoms. Int. Neurourol. J., 2020, 24(3), 231-240.
[http://dx.doi.org/10.5213/inj.2040082.041] [PMID: 33017894]
[26]
Gomm, W.; von Holt, K.; Thomé, F.; Broich, K.; Maier, W.; Fink, A.; Doblhammer, G.; Haenisch, B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol., 2016, 73(4), 410-416.
[http://dx.doi.org/10.1001/jamaneurol.2015.4791] [PMID: 26882076]
[27]
Goldstein, F.C.; Steenland, K.; Zhao, L.; Wharton, W.; Levey, A.I.; Hajjar, I. Proton pump inhibitors and risk of mild cognitive impairment and dementia. J. Am. Geriatr. Soc., 2017, 65(9), 1969-1974.
[http://dx.doi.org/10.1111/jgs.14956] [PMID: 28590010]
[28]
Ortiz-Guerrero, G.; Amador-Muñoz, D.; Calderón-Ospina, C.A.; López-Fuentes, D.; Nava Mesa, M.O. Proton pump inhibitors and dementia: physiopathological mechanisms and clinical consequences. Neural Plast., 2018, 2018, 5257285.
[http://dx.doi.org/10.1155/2018/5257285] [PMID: 29755512]

Rights & Permissions Print Cite
Article Metrics
7
2
© 2024 Bentham Science Publishers | Privacy Policy